

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI!	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/672,747	09/26/2003		Dror Nir	U 014817-5	1019
140	7590	07/07/2005	•	EXAM	INER
LADAS &			JAWORSKI, FRANCIS J		
26 WEST 61ST STREET NEW YORK, NY 10023			ART UNIT	PAPER NUMBER	
	,			3737	
_				DATE MAIL ED: 07/07/200	ς.

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/672,747	NIR, DROR
Office Action Summary	Examiner	Art Unit
	Jaworski Francis J.	3737
The MAILING DATE of this communication app Period for Reply A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (5) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a repl If NO period for reply is apposited above, the maintains statutory period Faihure to reply within the set or extended period for reply wait, by shault Any reply received by the Office bater than three months after the mailin spanned patent form vigitaritiment, See 37 CFR 1.704(b).	Y IS SET TO EXPIRE 3 MONTH: 136(a). In no evens, however, may a reply be in 137 within the statutory minimum of thirty (30) day will apply and will captine SIX (8) MONTHS from 138 will apply and will captine SIX (8) MONTHS from	(S) FROM noty fited is will be considered timely. the mailing data of this communication. 10 (25 U.S.C. & 133).
Status		
1) Responsive to communication(s) filed on 26 S	s action is non-final. Ince except for formal matters, pr	osecution as to the ments is 53 O.G. 213.
Disposition of Claims		
4) Claim(s) 8-10 and 18-21 is/are pending in the 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) 8-10 and 18-21 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/o	wn from consideration.	
9) The specification is objected to by the Examin- 10) The drawing(s) filed on <u>26 September 2003</u> is Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	/are: a)⊠ accepted or b)⊡ obje e drawing(s) be held in abeyance. Se ction is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to, See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some c) None of: 1. Certified copies of the priority document compared copies of the priority document copies of the certified copies of the priority document copies of the certified copies of the priority document copies of the certified copies of the priority document copies of the certified copies of the priority document copies of the certified copies of the priority document copies of the certified copies of the ce	als have been received. als have been received in Applica onity documents have been receiv au (PCT Rule 17.2(a)).	tion No ved in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date <u>26 September 2003</u> U.S Patent and Tradoman Office PTOL-326 (Rev. 1-04) Office A	6) Other:	

Page 2

Application/Control Number: 10/672,747

Art Unit: 3737

DETAILED ACTION

Claim Rejections - 35 USC § 102/103

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States

e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in-which the invention was made.

Claims 8-10 and 18-21 are present for examination per September 26,2003 pre-amdt.

Claims 8-9 and 18-20 are rejected under 35 U.S.C. 102(b,e) as being anticipated by Giger et al (US5657362) or in the alternative as obvious based upon Giger et al (US2001/0043279) or Gilhuijs et al (US6317617).

The former teaches thresholding to determine benign versus malignant mammograms with classification being tissue texture or irregularity-based histogram calculations and analysis done by the processor engine of an expert system performing computer-assisted diagnosis. The radiogram is argued to be produced by a process which involves attenuation of x-radiation and therefore is related to scattered or reflected radiation.

However if the former be argued to not represent detection of reflected or scattered waves in the sense of through-transmission radiographs then it would have

Page 3

Application/Control Number: 10/672,747

Art Unit: 3737

been obvious in view of the latter to use ultrasound per para [0070] of the published application or from Gilhuijs et al since ultrasound mammograms may be derived with out exposing the patient to harmful ionizing radiation.

Claims 10 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Giger et al '362 alone or further in view of Giger et al as applied to claims 9, 20 above, and further in view of Gilhuijs et al since the latter teaches the suitability of Fourier analysis by the neural network for evaluating texture abnormalities of tissue, see col. 12 lines 38-51 as exemplary.

Nishikawa et al (US6058322 and 5598481) and Asada et al (US5463548) are representative of neural network-based and wavelet-based analyses for discriminating malignant tissue based upon texture.

Miller (US6393157) discusses wavelet versus Fourier/entropy analyses for this purpose.

Smith et al (US5644232) is representative of an MRI-based system which uses thresholding and tissue texture/irregularity analysis by a neural network including entropy analysis to categorize tissue to determine if malignant.

Any inquiry concerning this communication should be directed to Jaworski Francis J. at telephone number 571-272-4738

FJJ:fjj

06252005

Francis J. Jaworski Primary Examiner